Currently, orexins are being studied as a therapeutic target for the treatment of AD, considering not only sleep disturbances but also their interactions with the Aβ and TAU proteins (key actors in the AD pathophysiology) [54,67]. This evidence concerns the gene MAPT and Alzheimer disease.